Cargando…

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies

A new generation of HIV broadly neutralizing antibodies (bnAbs) with remarkable potency, breadth and epitope diversity has rejuvenated interest in immunotherapeutic strategies. Potencies defined by in vitro IC(50) and IC(80) values (50 and 80% inhibitory concentrations) figure prominently into the s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Webb, Nicholas E., Montefiori, David C., Lee, Benhur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588098/ https://www.ncbi.nlm.nih.gov/pubmed/26416571 http://dx.doi.org/10.1038/ncomms9443

Ejemplares similares

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth
por: van Dorsten, Rebecca T., et al.
Publicado: (2021)

Bispecific antibodies combine breadth, potency, and avidity of parental antibodies to neutralize sarbecoviruses
por: Radić, Laura, et al.
Publicado: (2023)

IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody
por: Saito, Shinji, et al.
Publicado: (2019)

Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth
por: Chukwuma, Valentine U., et al.
Publicado: (2018)

Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design
por: Holt, Graham T., et al.
Publicado: (2023)

Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency
por: Frumento, Nicole, et al.
Publicado: (2022)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation
por: Crooks, Ema T., et al.
Publicado: (2018)

Antibody engineering for increased potency, breadth and half-life
por: Sievers, Stuart A., et al.
Publicado: (2015)

Broadly neutralizing monoclonal antibodies for HIV prevention
por: Miner, Maurine D., et al.
Publicado: (2021)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

P04-02. Increased breadth and potency of the neutralizing antibody response among dually-HIV-1-infected individuals
por: Powell, RL, et al.
Publicado: (2009)

Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies
por: Chikere, Kelechi, et al.
Publicado: (2014)

Complementary antibody lineages achieve neutralization breadth in an HIV-1 infected elite neutralizer
por: van Schooten, Jelle, et al.
Publicado: (2022)

Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth
por: Ku, Zhiqiang, et al.
Publicado: (2022)

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
por: McCoy, Laura E., et al.
Publicado: (2015)

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
por: Muecksch, Frauke, et al.
Publicado: (2021)

Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth
por: Ku, Zhiqiang, et al.
Publicado: (2022)

Changes in serum-neutralizing antibody potency and breadth post-SARS-CoV-2 mRNA vaccine boost
por: Nair, Manoj S., et al.
Publicado: (2023)

HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth
por: Sheward, Daniel J., et al.
Publicado: (2018)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses
por: Wang, Yingdan, et al.
Publicado: (2022)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody
por: Richardson, Simone I., et al.
Publicado: (2019)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
por: van Schooten, Jelle, et al.
Publicado: (2018)

The breadth of HIV-1 neutralizing antibodies depends on the conservation of key sites in their epitopes
por: Bai, Hongjun, et al.
Publicado: (2019)

Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth
por: Roskin, Krishna M., et al.
Publicado: (2020)

Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth
por: Cizmeci, Deniz, et al.
Publicado: (2021)

Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses
por: Jia, Janice Zhirong, et al.
Publicado: (2022)

Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
por: Hsu, Denise C., et al.
Publicado: (2021)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
por: Mayer, Bryan T., et al.
Publicado: (2022)

Diet Breadth Mediates the Prey Specificity of Venom Potency in Snakes
por: Lyons, Keith, et al.
Publicado: (2020)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Broadly Neutralizing Antibodies for HIV Eradication
por: Stephenson, Kathryn E., et al.
Publicado: (2016)

Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials
por: Montefiori, David C., et al.
Publicado: (2012)

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency
por: Easterhoff, David, et al.
Publicado: (2020)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine
por: Guo, Shuxin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bpktj5so6je4hk2ib53ualdn6r